LeMaitre Vascular Posts 11% Q3 Sales Growth
The Burlington, Massachusetts medical device maker reported third-quarter 2026 results and a $19.2 million acquisition of B. Braun vascular assets.
Updated on Nov. 4, 2026 in Corporate Finance
LeMaitre Vascular reported net sales of $68.0 million for the third quarter of 2026, up 11% from the prior-year quarter. The company also acquired certain vascular assets from B. Braun for $19.2 million in October.
Why it matters
The quarter shows organic growth of 12% alongside a 14% drop in earnings per share, as operating expenses rose 21%. The B. Braun acquisition and a higher full-year sales guidance point to continued expansion for the Massachusetts company.
Cash and short-term marketable securities totaled $390 million at September 30, 2026, against a $19.2 million acquisition price for the B. Braun assets. Operating income fell 13% to $17.7 million even as sales grew 11%.
The players
LeMaitre Vascular
A Burlington, Massachusetts medical device company focused on vascular surgery products, including grafts and shunts.
B. Braun
A German medical and pharmaceutical company whose vascular assets LeMaitre acquired in October 2026.
The details
LeMaitre reported 18% Artegraft sales growth in the quarter, with grafts and shunts driving the increase, and 12% organic growth made up of 7% price and 5% units. The Board also approved a quarterly dividend of $0.25 per share on October 27, 2026.
Timeline
September 30, 2026: Quarter end and balance sheet date.
October 2026: Acquisition of B. Braun vascular assets closes for $19.2 million.
October 27, 2026: Board approves $0.25 quarterly dividend.
November 4, 2026: Third-quarter results released and conference call held.
December 3, 2026: Quarterly dividend payment date.
Market Dynamics
LeMaitre's third-quarter results fit its full-year 2026 guidance of $274.8 million to $276.8 million in net sales and EPS of $2.77 to $2.82. The company is pairing that outlook with an acquisition, signaling it is using its cash position to expand its vascular product line.
Shareholders of record by November 19, 2026 are slated to receive the $0.25 quarterly dividend on December 3, 2026. Investors are watching whether the company's operating expenses, which rose 21%, can be controlled as it integrates new assets.
The takeaway
Revenue growth at LeMaitre is outpacing profit growth, with operating income down 13% despite the sales increase. Readers tracking the stock should watch whether operating expenses stabilize in the coming quarters.
Further reading
Track more company earnings in the Corporate Finance section.
Source note: This article includes information reported by The Manila times.
